Design Therapeutics Inc (NAS:DSGN)
$ 5.48 -0.36 (-6.16%) Market Cap: 310.28 Mil Enterprise Value: 72.07 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 42/100

Q4 2023 Design Therapeutics Inc Earnings Call Transcript

Mar 19, 2024 / 08:30PM GMT
Release Date Price: $2.59 (+2.78%)
Operator

And welcome to design's conference call at this time. All participants are in a listen only. There will be a question and answer session after that prepared be advised that this call is being recorded at the company's request. I would now like to turn the call over to Dr. Sean Jeffries, Chief Operating Officer of design Therapeutics.

Sean Jeffries
Design Therapeutics, Inc. - COO

Yes, welcome, and thank you for joining us today. Earlier we issued a press release outlining our fourth quarter and full year 2023 financial results and updates across our portfolio of gene tech, small molecule genomic medicines. The slides that we'll be using today during today's call will be available along with the recording of this call in the Investors section of our website at design team. I'm Sean Jefferies, Chief Operating Officer of design; and I'm joined today on the call by our Chairman and CEO, Dr. Pratik Shah.

Pratik Shah
Design Therapeutics, Inc. - Co-Founder, President, and Chairperson

During this call, we will use forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot